Blincyto (blinatumomab) / Astellas, Amgen 
Welcome,         Profile    Billing    Logout  
 29 Diseases   78 Trials   78 Trials   3560 News 


«12...1213141516171819202122...4445»
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol. (Pubmed Central) -  Jun 13, 2022   
    The knowledge gained in the formative assessment will reveal the priority areas and key implementation strategies. Thereby, the resultant roadmap will facilitate future scale-out strategies for novel therapies in LMICs, thus increasing access, building capacity for management, and ultimately improving the care for children in LMICs.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Enrollment closed:  Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Jun 9, 2022   
    P1,  N=44, Active, not recruiting, 
    Thereby, the resultant roadmap will facilitate future scale-out strategies for novel therapies in LMICs, thus increasing access, building capacity for management, and ultimately improving the care for children in LMICs. Suspended --> Active, not recruiting
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal, IO biomarker:  Visualizing Spatial and Stoichiometric Barriers to Bispecific T-cell Engager Efficacy. (Pubmed Central) -  Jun 8, 2022   
    Blinatumomab is approved for treatment of B-cell malignancies, but BiTE molecule development in solid tumors has been more challenging...We report that deletion of stimulatory conventional type I DCs (cDC1) diminished BiTE molecule-induced T-cell activation and tumor clearance, suggesting that in situ antigen-presenting cell (APC) engagements modulate the extent of BiTE molecule efficacy. In summary, our work identified multiple requirements for optimal BiTE molecule efficacy in solid tumors, providing insights that could be harnessed for solid cancer immunotherapy development.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal:  Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. (Pubmed Central) -  Jun 5, 2022   
    Since the first approval of blinatumomab by the United States Food and Drug Administration (US FDA), various bsAb-based ICEs have been developed for the effective treatment of patients with cancer...Therefore, this review focused on not only highlighting the action mechanism, design and structure, and status of bsAb-based ICEs in clinical development and their approval by the US FDA for human malignancy treatment, but also on summarizing the currently known and emerging therapeutic targets in cancer. This review provides insights into practical considerations for developing next-generation ICEs.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Journal:  The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL). (Pubmed Central) -  Jun 4, 2022   
    Most impressive is the advent of chimeric antigen receptor cell therapy (CAR-T), a curative therapy in a significant proportion of younger patients with RR-ALL. Careful consideration is now required in the selection of relapse therapies; this review summarizes current available strategies and how to navigate the treatment landscape for RR ALL.
  • ||||||||||  Journal:  Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. (Pubmed Central) -  Jun 4, 2022   
    P1, P1/2,
    Monoclonal antibodies are proven to be a promising immunotherapeutic strategy to improve ALL patients' outcome in the long term. There's still a need for individualized treatment with effective and well-tolerated medicines.Trial registration: ClinicalTrials.gov identifier: NCT01363128.Trial registration: ClinicalTrials.gov identifier: NCT01466179.Trial registration: ClinicalTrials.gov identifier: NCT02013167.Trial registration: ClinicalTrials.gov identifier: NCT02000427.Trial registration: ClinicalTrials.gov identifier: NCT01564784.Trial registration: ClinicalTrials.gov identifier: NCT03677596.Trial registration: ClinicalTrials.gov identifier: NCT01363297.Trial registration: ClinicalTrials.gov identifier: NCT02981628.Trial registration: ClinicalTrials.gov identifier: NCT03094611.Trial registration: ClinicalTrials.gov identifier: NCT01371630.Trial registration: ClinicalTrials.gov identifier: NCT04224571.Trial registration: ClinicalTrials.gov identifier: NCT02458014.Trial registration: ClinicalTrials.gov identifier: NCT04546399.Trial registration: ClinicalTrials.gov identifier: NCT02879695.Trial registration: ClinicalTrials.gov identifier: NCT03913559.Trial registration: ClinicalTrials.gov identifier: NCT03441061.Trial registration: ClinicalTrials.gov identifier: NCT03739814.Trial registration: ClinicalTrials.gov identifier: NCT02877303.Trial registration: ClinicalTrials.gov identifier: NCT03698552.Trial registration: ClinicalTrials.gov identifier: NCT04601584.Trial registration: ClinicalTrials.gov identifier: NCT04684147.Trial registration: ClinicalTrials.gov identifier: NCT04681105.
  • ||||||||||  Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Journal, IO biomarker:  Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy. (Pubmed Central) -  Jun 4, 2022   
    However, deep molecular remission was recaptured with a combination of blinatumomab and ponatinib, so he could proceed to allotransplantation. This case illustrates that next-generation sequencing approaches designed to discover cryptic gene fusions can benefit patients with Ph-like ALL.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date, Combination therapy:  Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  May 23, 2022   
    P1/2,  N=36, Recruiting, 
    The safety and efficacy of blinatumomab in Asian patients were comparable with those reported in previous global studies with no new safety signals. Trial completion date: Apr 2022 --> Apr 2024 | Trial primary completion date: Apr 2022 --> Apr 2024
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies. (Pubmed Central) -  May 21, 2022   
    Blinatumomab is the first bispecific antibody that received FDA approval for relapsed refractory B cell precursor acute lymphoblastic leukemia...Other bispecific antibodies are under clinical investigation for multiple myeloma and acute myeloid leukemia. Along with immune checkpoint inhibitors and chimeric antigen T cell receptor therapies, bispecific antibodies are considered a mainstay as a therapeutic option for cancer immunotherapies for Hematologic malignancies.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Preclinical, Journal:  BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. (Pubmed Central) -  May 14, 2022   
    Pre-emptive IVIG repletion during blinatumomab did not prevent hypogammaglobulinemia and associated infection risk. In conclusion, we propose that nilotinib and imatinib might also be suitable substances for combination with blinatumomab and suggest evaluation in clinical trials.
  • ||||||||||  obecabtagene autoleucel (AUTO1) / Autolus, AUTO3 / Autolus
    DUAL ANTIGEN TARGETING WITH CO-TRANSDUCED CD19/22 CAR T CELLS FOR RELAPSED/REFRACTORY ALL (Hall Strauss 1-2) -  May 13, 2022 - Abstract #EHA2022EHA_2708;    
    P1
    Following fludarabine/cyclophosphamide lymphodepletion, patients received 1x10 6 /kg CAR + T cells...Five of 8 patients had relapsed post allogeneic SCT, 4 had received prior Blinatumomab/Inotuzumab and 3 had relapsed after prior Tisagenlecleucel...CAR T cell products had a central memory phenotype with predominance of CD19/22 double positive cells (median 59.3%) and balanced populations of CD19 and CD22 single positive cells (16% and 10.9% respectively).Cytokine release syndrome (CRS) occurred in 7/8 patients (grade 1 n=2 , grade 2 n=5 ) requiring Tocilizumab in 3 cases, but severe (≥ grade 3) CRS was not seen and no patients required ICU admission for CRS...Conclusion We demonstrate that dual CD19/22 targeting CAR T cells generated by co-transduction show an acceptable safety profile, with robust expansion/persistence and early efficacy in a heavily pre-treated cohort. To date with limited follow-up we have not observed antigen negative relapse but longer follow up is needed.
  • ||||||||||  Oncaspar liquid (pegaspargase) / Servier
    NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS. (Hall Strauss 3) -  May 13, 2022 - Abstract #EHA2022EHA_2615;    
    P2
    Toxicity of grade 2 or more was mainly observed at course 1 (hepatic 12.8%, coagulation/thrombosis 3.2% [enoxaparin prophylaxis recommended with platelets >30-50], pancreatic 1.6%), contributing to an induction death in 3 patients (1.4%), but was rare afterwards...The results were more favorable in patients up to the age of 55, especially in those aged 18-40 years, and in those who achieved maximum MRD response regardless of age (Figure). Subsequently, a pegaspargase dosing algorithm based on patient age, body mass index, hepatosteatosis and selected toxicities at first or prior drug exposure was developed to minimize toxicity, and was used in a successor GIMEMA trial of sequential chemotherapy-blinatumomab for CD19+ adult B-ALL.